Kos Biotechnology Partners Secures $123 Million in Third Closing of Inaugural Global Life Sciences Fund

Kos Biotechnology Partners, a global life sciences investment firm, has announced the third closing of its inaugural global life sciences fund, bringing total capital commitments to $123 million. This significant milestone marks a major achievement for the firm, which aims to bridge the US biopharma ecosystem with Europe. Founded by Dr. Simos Simeonidis and Alex Tzoukas, Kos Biotechnology Partners is the first life sciences-dedicated investment fund in Greece and has secured backing from prominent institutional investors, including lead investor Hellenic Development Bank of Investments (HDBI), and global family offices.

The firm's strategic approach involves deploying capital flexibly across all stages of development, from company formation through Series C. Kos targets high-impact investments in three core life sciences subsectors: biotech/novel therapeutics, pharma services, and tech-enabled technologies. This approach is driven by the convergence of novel biology with data science and advanced computing, creating unprecedented opportunities to cure complex diseases. As Dr. Simos Simeonidis, Co-Founder and Managing Partner, noted, 'Our mission is to back exceptional entrepreneurs redefining the standard of care by leveraging our proprietary international network to connect US drug development know-how with specialized scientific talent.'

Kos Biotechnology Partners was founded with the vision to build the life sciences ecosystem in Greece, combining elite Wall Street institutional investing expertise with deep scientific domain knowledge. The firm's ability to invest flexibly across all growth stages ensures that it can function as a committed, long-term operational partner to innovators transforming human health. As Alex Tzoukas, Co-Founder and Managing Partner, added, 'Securing our third closing at $123 million in just a few months validates our cross-border thesis and underscores the immense potential of bridging US scientific innovation and drug development expertise with Europe's advancing life sciences ecosystem.'

The firm's investment strategy is supported by an elite advisory network comprising prominent industry leaders drawn from the Greek diaspora in the United States. This network brings together world-class scientific minds, clinical experts, and corporate biopharma executives who bridge international networks to help portfolio companies scale globally. Demonstrating strong operational momentum, Kos has already completed its first two investments, including leading the recent financing round for tech-enabled pharma services provider Epikast, alongside a strategic investment in a San Francisco-based biotechnology company to be announced soon.

Kos Biotechnology Partners' achievement is significant not only for the firm but also for the life sciences industry as a whole. The firm's commitment to bridging the US and European life sciences ecosystems has the potential to unlock new opportunities for innovation and collaboration. With its inaugural global life sciences fund, Kos is well-positioned to support the development of groundbreaking therapies and technologies that can transform human health. As the firm continues to grow and expand its investment portfolio, it is likely to play an increasingly important role in shaping the future of the life sciences industry.

In conclusion, Kos Biotechnology Partners' securing of $123 million in its third closing is a testament to the firm's strategic vision and commitment to the life sciences industry. With its unique approach to investing and its elite advisory network, Kos is poised to make a significant impact on the development of innovative therapies and technologies. As the life sciences industry continues to evolve, firms like Kos Biotechnology Partners will be essential in driving progress and innovation.